Tag - WINT

Developments

Windtree highlights abstract on istaroxime presented at 2025 THT conference

Windtree Therapeutics (NasdaqCM:WINT) has announced that an abstract discussing the positive results of SEISMiC, its Phase 2b study of istaroximine in cardiogenic shock, was presented by Dr. Matteo Pagnesi, a...

February 12, 2025

Developments

Windtree doses first patient in Phase 2 cardiogenic shock study

Windtree Therapeutics (NASDAQCM:WINT) dosed the first patient in its Phase 2 study evaluating istaroxime in patients with early cardiogenic shock due to heart failure. Cardiogenic shock is a condition where the heart...

October 1, 2020

Tag - WINT

Windtree highlights abstract on istaroxime presented at 2025 THT conference

Windtree doses first patient in Phase 2 cardiogenic shock study

Subscribe